Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Succinate dehydrogenase complex assembly factor 3 (SDHAF3)
- Target
- SDHAF3
- Molecular classification
- Assembly factor, Other (Mitochondrial assembly factor)
01
Overview
Succinate dehydrogenase complex assembly factor 3 (SDHAF3) is a mitochondrial protein that acts as an essential assembly factor for succinate dehydrogenase (also known as complex II of the mitochondrial electron transport chain). It is required for the proper assembly of complex II by promoting the maturation and protection of the SDHB subunit, specifically protecting it from oxidative damage. SDHAF3 is localized to the mitochondria and is involved in cellular energy metabolism by facilitating the function of the electron transport chain and the tricarboxylic acid (TCA) cycle. Its deficiency has been linked to mitochondrial respiratory disorders and possibly some cancers, though it is not itself a direct therapeutic target[1][5]. None currently reported specifically for SDHAF3. Dysfunction in SDHAF3 could (by analogy) result in impaired SDH complex function, which is sometimes monitored by metabolic markers (succinate accumulation), but SDHAF3-specific biomarkers are not established[1].
02
Mechanism of action
Not applicable; no direct drug mechanisms known for this protein.
03
Biological functions
Mitochondrial respiratory chain complex II assemblyRegulation of gluconeogenesisSuccinate metabolic processPromotion of maturation of the SDHB (iron-sulfur) subunit
04
Disease associations
Cancer (Defects in SDH assembly are associated with several tumor syndromes, but direct associations with SDHAF3 remain limited)Combined oxidative phosphorylation deficiency 8Pheochromocytoma (by analogy with other SDH assembly factor mutations)
05
Safety considerations
Mutations or dysfunction could lead to destabilization or defective assembly of succinate dehydrogenase, which is associated with mitochondrial dysfunction, impaired energy metabolism, and tumorigenesis in other SDH factors[1][6]. There are no drug-related safety issues since it is not a drug target.
Beyond the preview
Go deeper on Succinate dehydrogenase complex assembly factor 3 (SDHAF3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Succinate dehydrogenase complex assembly factor 3 (SDHAF3).